Chronic pansinusitis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients with chronic rhinosinusitis unresponsive to clinical drug treatment; patients with indication for endoscopic sinus surgery; older than 18 years
Exclusion criteria
Exclusion criteria: Patients who have a history of prior sinonasal surgery; patients with a history of smoking; patients with a history of systemic diseases that compromise the airway or irregularities in mucociliary transport, such as asthma or cystic fibrosis; patients with upper airway infection during the three weeks prior to surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome: Observe a reduction in symptoms for both groups, with control of the underlying disease. However, due to the antiseptic effects of Bluem, it is expected that group 1 will present fewer symptoms, especially in the first few weeks.;Outcome found: Bluem, like the saline solution, did not present any reports of serious or intolerable side effects. Comparisons between groups did not demonstrate statistically significant differences, and both groups showed improvements in symptoms. In intragroup assessments for the SNOT-22 questionnaire and VAS scale, a reduction in symptoms was observed for both groups, and in group 1 this significant reduction already appeared 15 days after surgery. However, this reduction was not sustained at the 60-day PO follow-up. In group 2, the significant reduction appeared at the 30- and 60-day PO follow-ups. | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected. | — |
Countries
Brazil
Contacts
Hospital Paranaense de Otorrinolaringologia